Cargando…

Simultaneous Pharmacologic Inhibition of Yes‐Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic‐co‐Glycolic) Acid–Encapsulated Microparticles Improves Pulmonary Hypertension

BACKGROUND: Pulmonary hypertension (PH) is a deadly disease characterized by vascular stiffness and altered cellular metabolism. Current treatments focus on vasodilation and not other root causes of pathogenesis. Previously, it was demonstrated that glutamine metabolism, as catalyzed by GLS1 (glutam...

Descripción completa

Detalles Bibliográficos
Autores principales: Acharya, Abhinav P., Tang, Ying, Bertero, Thomas, Tai, Yi‐Yin, Harvey, Lloyd D., Woodcock, Chen‐Shan C., Sun, Wei, Pineda, Ricardo, Mitash, Nilay, Königshoff, Melanie, Little, Steven R., Chan, Stephen Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477870/
https://www.ncbi.nlm.nih.gov/pubmed/34056915
http://dx.doi.org/10.1161/JAHA.120.019091
_version_ 1784575936656572416
author Acharya, Abhinav P.
Tang, Ying
Bertero, Thomas
Tai, Yi‐Yin
Harvey, Lloyd D.
Woodcock, Chen‐Shan C.
Sun, Wei
Pineda, Ricardo
Mitash, Nilay
Königshoff, Melanie
Little, Steven R.
Chan, Stephen Y.
author_facet Acharya, Abhinav P.
Tang, Ying
Bertero, Thomas
Tai, Yi‐Yin
Harvey, Lloyd D.
Woodcock, Chen‐Shan C.
Sun, Wei
Pineda, Ricardo
Mitash, Nilay
Königshoff, Melanie
Little, Steven R.
Chan, Stephen Y.
author_sort Acharya, Abhinav P.
collection PubMed
description BACKGROUND: Pulmonary hypertension (PH) is a deadly disease characterized by vascular stiffness and altered cellular metabolism. Current treatments focus on vasodilation and not other root causes of pathogenesis. Previously, it was demonstrated that glutamine metabolism, as catalyzed by GLS1 (glutaminase 1) activity, is mechanoactivated by matrix stiffening and the transcriptional coactivators YAP1 (yes‐associated protein 1) and transcriptional coactivator with PDZ‐binding motif (TAZ), resulting in pulmonary vascular proliferation and PH. Pharmacologic inhibition of YAP1 (by verteporfin) or glutaminase (by CB‐839) improved PH in vivo. However, systemic delivery of these agents, particularly YAP1 inhibitors, may have adverse chronic effects. Furthermore, simultaneous use of pharmacologic blockers may offer additive or synergistic benefits. Therefore, a strategy that delivers these drugs in combination to local lung tissue, thus avoiding systemic toxicity and driving more robust improvement, was investigated. METHODS AND RESULTS: We used poly(lactic‐co‐glycolic) acid polymer‐based microparticles for delivery of verteporfin and CB‐839 simultaneously to the lungs of rats suffering from monocrotaline‐induced PH. Microparticles released these drugs in a sustained fashion and delivered their payload in the lungs for 7 days. When given orotracheally to the rats weekly for 3 weeks, microparticles carrying this drug combination improved hemodynamic (right ventricular systolic pressure and right ventricle/left ventricle+septum mass ratio), histologic (vascular remodeling), and molecular markers (vascular proliferation and stiffening) of PH. Importantly, only the combination of drug delivery, but neither verteporfin nor CB‐839 alone, displayed significant improvement across all indexes of PH. CONCLUSIONS: Simultaneous, lung‐specific, and controlled release of drugs targeting YAP1 and GLS1 improved PH in rats, addressing unmet needs for the treatment of this deadly disease.
format Online
Article
Text
id pubmed-8477870
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84778702021-10-01 Simultaneous Pharmacologic Inhibition of Yes‐Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic‐co‐Glycolic) Acid–Encapsulated Microparticles Improves Pulmonary Hypertension Acharya, Abhinav P. Tang, Ying Bertero, Thomas Tai, Yi‐Yin Harvey, Lloyd D. Woodcock, Chen‐Shan C. Sun, Wei Pineda, Ricardo Mitash, Nilay Königshoff, Melanie Little, Steven R. Chan, Stephen Y. J Am Heart Assoc Original Research BACKGROUND: Pulmonary hypertension (PH) is a deadly disease characterized by vascular stiffness and altered cellular metabolism. Current treatments focus on vasodilation and not other root causes of pathogenesis. Previously, it was demonstrated that glutamine metabolism, as catalyzed by GLS1 (glutaminase 1) activity, is mechanoactivated by matrix stiffening and the transcriptional coactivators YAP1 (yes‐associated protein 1) and transcriptional coactivator with PDZ‐binding motif (TAZ), resulting in pulmonary vascular proliferation and PH. Pharmacologic inhibition of YAP1 (by verteporfin) or glutaminase (by CB‐839) improved PH in vivo. However, systemic delivery of these agents, particularly YAP1 inhibitors, may have adverse chronic effects. Furthermore, simultaneous use of pharmacologic blockers may offer additive or synergistic benefits. Therefore, a strategy that delivers these drugs in combination to local lung tissue, thus avoiding systemic toxicity and driving more robust improvement, was investigated. METHODS AND RESULTS: We used poly(lactic‐co‐glycolic) acid polymer‐based microparticles for delivery of verteporfin and CB‐839 simultaneously to the lungs of rats suffering from monocrotaline‐induced PH. Microparticles released these drugs in a sustained fashion and delivered their payload in the lungs for 7 days. When given orotracheally to the rats weekly for 3 weeks, microparticles carrying this drug combination improved hemodynamic (right ventricular systolic pressure and right ventricle/left ventricle+septum mass ratio), histologic (vascular remodeling), and molecular markers (vascular proliferation and stiffening) of PH. Importantly, only the combination of drug delivery, but neither verteporfin nor CB‐839 alone, displayed significant improvement across all indexes of PH. CONCLUSIONS: Simultaneous, lung‐specific, and controlled release of drugs targeting YAP1 and GLS1 improved PH in rats, addressing unmet needs for the treatment of this deadly disease. John Wiley and Sons Inc. 2021-05-29 /pmc/articles/PMC8477870/ /pubmed/34056915 http://dx.doi.org/10.1161/JAHA.120.019091 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Acharya, Abhinav P.
Tang, Ying
Bertero, Thomas
Tai, Yi‐Yin
Harvey, Lloyd D.
Woodcock, Chen‐Shan C.
Sun, Wei
Pineda, Ricardo
Mitash, Nilay
Königshoff, Melanie
Little, Steven R.
Chan, Stephen Y.
Simultaneous Pharmacologic Inhibition of Yes‐Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic‐co‐Glycolic) Acid–Encapsulated Microparticles Improves Pulmonary Hypertension
title Simultaneous Pharmacologic Inhibition of Yes‐Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic‐co‐Glycolic) Acid–Encapsulated Microparticles Improves Pulmonary Hypertension
title_full Simultaneous Pharmacologic Inhibition of Yes‐Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic‐co‐Glycolic) Acid–Encapsulated Microparticles Improves Pulmonary Hypertension
title_fullStr Simultaneous Pharmacologic Inhibition of Yes‐Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic‐co‐Glycolic) Acid–Encapsulated Microparticles Improves Pulmonary Hypertension
title_full_unstemmed Simultaneous Pharmacologic Inhibition of Yes‐Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic‐co‐Glycolic) Acid–Encapsulated Microparticles Improves Pulmonary Hypertension
title_short Simultaneous Pharmacologic Inhibition of Yes‐Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic‐co‐Glycolic) Acid–Encapsulated Microparticles Improves Pulmonary Hypertension
title_sort simultaneous pharmacologic inhibition of yes‐associated protein 1 and glutaminase 1 via inhaled poly(lactic‐co‐glycolic) acid–encapsulated microparticles improves pulmonary hypertension
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477870/
https://www.ncbi.nlm.nih.gov/pubmed/34056915
http://dx.doi.org/10.1161/JAHA.120.019091
work_keys_str_mv AT acharyaabhinavp simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT tangying simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT berterothomas simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT taiyiyin simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT harveylloydd simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT woodcockchenshanc simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT sunwei simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT pinedaricardo simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT mitashnilay simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT konigshoffmelanie simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT littlestevenr simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension
AT chanstepheny simultaneouspharmacologicinhibitionofyesassociatedprotein1andglutaminase1viainhaledpolylacticcoglycolicacidencapsulatedmicroparticlesimprovespulmonaryhypertension